Evidence map›Paper›PMID 27265756›Full record

Observational studyDiabetes, obesity & metabolism2016

Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39).

Dennis Schrijnders, Raiza Wever, Nanne Kleefstra, Sebastiaan T Houweling, Kornelis J J van Hateren, Geertruida H de Bock, Henk J G Bilo, Klaas H Groenier, Gijs W D Landman

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Diabetes, obesity & metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Heart Failure in Type 2 Diabetes Mellitus.Circulation research · 2019
    Review
  4. Review
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Dennis SchrijndersDiabetes Centre, Isala, Zwolle, The Netherlands. d.schrijnders@isala.nl.
Raiza WeverDiabetes Centre, Isala, Zwolle, The Netherlands.
Nanne KleefstraDiabetes Centre, Isala, Zwolle, The Netherlands.
Sebastiaan T HouwelingDiabetes Centre, Isala, Zwolle, The Netherlands.
Kornelis J J van HaterenDiabetes Centre, Isala, Zwolle, The Netherlands.
Geertruida H de BockDepartment of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Henk J G BiloDiabetes Centre, Isala, Zwolle, The Netherlands.
Klaas H GroenierDepartment of General Practice, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Gijs W D LandmanDiabetes Centre, Isala, Zwolle, The Netherlands.
Isala · NLKatholieke Pabo Zwolle · NLUniversity Medical Center Groningen · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate changes in body weight trajectories after the addition of individual sulphonylureas (SUs) to metformin in patients with type 2 diabetes. MATERIALS AND

methodsWe conducted a retrospective observational cohort study, in a primary care setting in the Netherlands. Patients aged ≥18 years with type 2 diabetes who were included in the ZODIAC cohort between 1998 and 2012 and who received metformin monotherapy at inclusion (n = 29 195), and had used metformin as monotherapy for at least 1 year before receiving dual therapy through the addition of an SU for at least 1 year were eligible for inclusion. The primary outcome was within-drug yearly change in body weight after receiving add-on therapy with individual SUs during 5 years of follow-up. The secondary outcome was within-drug yearly change in glycated haemoglobin (HbA1c). Annual changes in weight and HbA1c were estimated with linear mixed models, adjusted for age, gender and diabetes duration.

resultsA total of 2958 patients were included. No significant weight changes were observed within and between any of the individual SUs after treatment intensification (p = 0.24). In addition, no significant difference in weight between the add-on therapy combinations was observed (p = 0.26). The average HbA1c the year before intensification was 7.2% (55 mmol/mol) and dropped below 7.0% (53 mmol/mol) the year after.

conclusionsIn patients with type 2 diabetes treated in primary care, strict glycaemic control can be maintained with SUs used as add-on therapy to metformin, without the offset of relevant weight changes.

Indexed as

AgedBlood GlucoseBody WeightDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemic AgentsMaleMetforminMiddle AgedRetrospective StudiesSulfonylurea CompoundsBlood GlucoseGlycated HemoglobinHypoglycemic AgentsMetforminSulfonylurea Compoundsblood glucosebody weightdiabetes mellitus type 2humansmetforminprospective studiessulphonylurea compounds

Identifiers

PMID27265756
PMCPMC5129585
OpenAlexW2413612252

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.